Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trial for the treatment of patients with platinum-resistant ARID1a-mutated ovarian carcinoma. The company is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Nuvectis Pharma, Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Nuvectis Pharma (NVCT) and EyePoint Pharmaceuticals ...

Analysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT) and EyePoint Pharmaceuticals (EYPT)

In a report released yesterday, Naz Rahman from Maxim Group reiterated a Buy rating on Nuvectis Pharma, with a price target of $30.00. Rahman cover...

Maxim Group Keeps Their Buy Rating on Nuvectis Pharma (NVCT)

WSW, NY, July 23rd, 2026, FinanceWire Nuvectis Pharma (NASDAQ:NVCT) announced this morning that ciprocopan (NXP100) has been approved by China’s Na...

Nuvectis’ NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor

Nuvectis Pharma, Inc. ($NVCT) announced an update on their ongoing clinical study. The Phase 1b clinical study titled “A Phase 1b Clinical Study of...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NVCT	$18.95	+0.64%	171.97K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NVCT	$18.95	+0.6%	171.97K
3
4
5
6

NVCT

NVCT

Get Nuvectis Pharma, Inc. Data in Excel

Get Nuvectis Pharma, Inc. Data in Excel